Rising Bearish Sentiment in BEAM
Beam Therapeutics Inc. (BEAM) has emerged as a high-conviction target for short sellers, with recent data indicating a substantial increase in open short positions. As of the August 31, 2026, settlement, short interest reached 25.8 million shares, representing approximately 25% of the company's total shares outstanding. This places the stock in the top 7% of heavily shorted names tracked by market analytics.
Sustained Short Accumulation
This is not a transient move; shorts have aggressively added to their positions over four consecutive settlement periods. The short interest has climbed steadily from 23.6% of shares outstanding at the previous reading. With a 'days to cover' ratio standing at 14.8, the stock exhibits a high level of technical vulnerability should a catalyst trigger a short squeeze. While the current borrow fee remains relatively modest at 0.3%, the sheer volume of the open interest suggests a significant institutional bet against the company's near-term performance.
Signal data sourced from CurvedTrading. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.